The correlation analysis of TERT promoter mutations with IDH1/2 mutations and 1p/19q detected in human gliomas

por Xu, Jie, Xu, Fang-Ping, Liu, Zhi-Hua, Cui, Qian, Zhang, Ke-Ping, Li, Zhi
Publicado 2022

Deep learning with biopsy whole slide images for pretreatment prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer：A multicenter study

por Li, Bao, Li, Fengling, Liu, Zhenyu, Xu, FangPing, Ye, Guolin, Li, Wei, Zhang, Yimin, Zhu, Teng, Shao, Lizhi, Chen, Chi, Sun, Caixia, Qiu, Bensheng, Bu, Hong, Wang, Kun, Tian, Jie
Publicado 2022

Overexpression of SRC‐3 promotes esophageal squamous cell carcinoma aggressiveness by enhancing cell growth and invasiveness

por Xu, Fang‐Ping, Liu, Yan‐Hui, Luo, Xin‐Lan, Zhang, Fen, Zhou, Hai‐Yu, Ge, Yan, Liu, Chao, Chen, Jie, Luo, Dong‐Lan, Yan, Li‐Xu, Mei, Ping, Xu, Jie, Zhuang, Heng‐Guo
Publicado 2016

Immunophenotypic features and t(14;18) (q32;q21) translocation of Chinese follicular lymphomas helps to distinguish subgroups

por Zhang, Fen, Yan, Li-Xu, Lin, Su-Xia, Ye, Zi-Yin, Zhuang, Heng-Guo, Yun, Jing-Ping, Lin, Han-Liang, Luo, Dong-Lan, Xu, Fang-Ping, Luo, Xin-Lan, Cheng, Jie, Zhang, Ke-Ping, Liu, Yan-Hui
Publicado 2013

PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer

por YAN, LI-XU, LIU, YAN-HUI, XIANG, JIAN-WEN, WU, QI-NIAN, XU, LEI-BO, LUO, XIN-LAN, ZHU, XIAO-LAN, LIU, CHAO, XU, FANG-PING, LUO, DONG-LAN, MEI, PING, XU, JIE, ZHANG, KE-PING, CHEN, JIE
Publicado 2015

Pathological Responses of the Primary Tumor and Locoregional Lymph Nodes After Neoadjuvant Immunochemotherapy in Esophageal Squamous Cell Cancer

por Huang, Shu Jie, Tian, Dan, Wang, Si Chao, Zeng, Rui Jie, Dong, Yue Jiao, Hong, Liang Li, Wu, Han Sheng, Xu, Fang Ping, Zhang, Dong Kun, Xie, Liang, Zhou, Hai Yu, Tang, Ji Ming, Ben, Xiao Song, Chen, Gang, Chen, Ri Xin, Tang, Yong, Qiao, Gui Bin
Publicado 2022

High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer

por Feng, Hui‐Bo, Chen, Yu, Xie, Zhi, Jiang, Jie, Zhong, Yu‐Min, Guo, Wei‐Bang, Yan, Wen‐Qing, Lv, Zhi‐Yi, Lu, Dan‐Xia, Liang, Hong‐Ling, Xu, Fang‐Ping, Yang, Jin‐Ji, Yang, Xue‐Ning, Zhou, Qing, Zhang, Dong‐Kun, Zhang, Zhou, Chuai, Shao‐Kun, Zhang, Heng‐Hui, Wu, Yi‐Long, Zhang, Xu‐Chao
Publicado 2021